Liu Lihong
Professor, PhD Supervisor
Research Interests: Pharmacology, Metabolomics, Pharmacogenomics, Clinical Pharmacy
Tel: +86-010-84205559
Email: hongllh@126.com
EDUCATION
Doctor of Medicine, The Fourth Military Medical University (2001)
Master of Medicine, Xi'an Medical University (1997)
Bachelor of Science, Shenyang Pharmaceutical University (1990)
PROFESSIONAL EXPERIENCE
2021–Present China–Japan Friendship Hospital, Beijing, China
Director, Scientific Research Center (Research Administration Office)
Director, Department of Pharmacy
Director, Drug Clinical Trial Institute
Chief Pharmacist
March 2012 -March 2021 Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Director, Department of Pharmacy
Chief Pharmacist
November 2003-March 2012 PLA Rocket Force Characteristic Medical Center, Beijing, China
Director, Department of Pharmacy
August 2001 – November 2003 Academy of Military Medical Sciences, Institute of Toxicology and Pharmacology
Postdoctoral Research Fellow
ACADEMIC APPOINTMENTS
Chair, Pharmaceutical Service Committee, Chinese Pharmaceutical Association
Chair, Pharmaceutical Committee, China Medical Women’s Association
Chair, Committee on Collaborative Development of New Medical Technologies, China National Health Association
Member of the Standing Committee, Society of Clinical Pharmacy, Chinese Medical Association
Member of the Standing Committee, Society of Rare Diseases, Chinese Medical Association
Chair, Clinical Pharmacy Committee, Beijing Medical Association
Chair, Committee on Clinical Research and Translation, Beijing Pharmaceutical Association
AWARDS AND CERTIFICATES
National Advanced Worker in the Health System (2025)
Wuzhou Women’s Science and Technology Award, 8th Edition, China Medical Women’s Association (2023)
Most Beautiful Science and Technology Worker, Chinese Pharmaceutical Association (2021)
Title of “Exemplary Role Model”, National Distinguished Doctors Program (2020)
Third Prize, Beijing Medical Science and Technology Award (2020)
Third Prize, National Award for Clinical Innovation (2020)
Third Prize, Military Science and Technology Progress Award (2012)
REPRESENTATIVE PUBLICATIONS
1. Yang, Song# ;Yan, Longxin ;Chen, Lang ;Su, Gaijuan ;Yang, Long ;Gong, Lili* ;Liu, Lihong*. Cardiac PDK4 promotes neutrophilic PFKL methylation and drives the innate immune response in diabetic myocardial infarction.PHARMACOLOGICAL RESEARCH. 10.1016/j.phrs.2025.107731.(SCIE, Q1, IF-2025=10.5)
2. Liu, Donghai# ;Chen, Lang ;Wang, Zai ;Li, Zecheng ;Liu, Lihong* ;Peng, Liang*. Ubiquitination of TFEB increased intestinal permeability to aggravate metabolic dysfunction-associated steatohepatitis.HEPATOLOGY.10.1097/HEP.0000000000001214.(SCIE, Q1, IF-2025=16.8)
3. Zhang, Yi ;Li, Qin-shan ;Liu, Hong-lin ;Tang, Hong-ting ;Yang, Han-lin ;Wu, Dao-qiu ;Huang, Yu-ying ;Li, Li-cheng ;Liu, Li-hong ;Li, Meng-xing*.MKRN1 promotes colorectal cancer metastasis by activating the TGF-β signalling pathway through SNIP1 protein degradation. (vol 42, 219, 2023). JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH.10.1186/s13046-023-02788-w.(SCIE, Q1, IF-2025=12.8)
4. Cheng, Longhao# ;Wang, Xiaoxue ;Liu, Aijun ;Zhu, Ying ;Cheng, Hu ;Yu, Jiangling ;Gong, Lili* ;Liu, Honglin* ;Shen, Guolin ;Liu, Lihong*.Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis (vol 14, pg 3493, 2024).ACTA PHARMACEUTICA SINICA B.10.1016/j.apsb.2024.04.021.(SCIE, Q1,IF-2024=14.6)
5. Lu, An ;Xu, Zhiyi ;Zhao, Zhixia ;Yan, Yi ;Jiang, Linxia ;Geng, Jing ;Jin, Hongwei ;Wang, Xiangyu ;Liu, Xiaoyan ;Zhu, Yuanjun ;Shi, Yujie ;Liu, Lihong ;Dai, Huaping ;Wang, Jian-Cheng. Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis.ADVANCED SCIENCE.10.1002/advs.202405406.(SCIE, Q1,IF-2024=14.1)
6. Li, Yanchuan# ;Li, Huamei# ;Peng, Cheng ;Meng, Ge ;Lu, Yijun ;Liu, Honglin ;Cui, Li ;Zhou, Huan ;Xu, Zhu ;Sun, Lingyun ;Liu, Lihong* ;Xiong, Qing* ;Sun, Beicheng* ;Jiao, Shiping*.Unraveling the spatial organization and development of human thymocytes through integration of spatial transcriptomics and single-cell multi-omics profiling. NATURE COMMUNICATIONS.10.1038/s41467-024-51767-y .(SCIE, Q1,IF-2024=15.7)
7. Zhang, Yijia# ;Qiao, Yuan ;Li, Zecheng ;Liu, Donghai ;Jin, Qi ;Guo, Jing ;Li, Xin ;Chen, Long* ;Liu, Lihong* ;Peng, Liang*.Intestinal NSD2 Aggravates Nonalcoholic Steatohepatitis Through Histone Modifications. ADVANCED SCIENCE.10.1002/advs.202402551.(SCIE, Q1,IF-2024=14.1)
8. Lu, Wenchao# ;Guo, Qixiang ;Ma, Zhuo ;Liu, Lihong* ;Zhao, Zhixia*. Lenvatinib and osteonecrosis of the jaw: A pharmacovigilance study.EUROPEAN JOURNAL OF CANCER.10.1016/j.ejca.2021.03.046.(SCIE, Q1,IF-2021=10.002)
9. Guo, Qixiang# ;Lu, Wenchao# ;Sun, Ximu ;Zhao, Zhixia* ;Liu, Lihong*.Anti-angiogenic agent-associated adrenal insufficiency in immune checkpoint inhibitors-treated patients.EUROPEAN JOURNAL OF CANCER.10.1016/j.ejca.2021.08.038.(SCIE, Q1,IF-2021=10.002)
10. Ye, Zhikang ;Blaser, Annika Reintam ;Lytvyn, Lyubov ;Wang, Ying ;Guyatt, Gordon H. ;Mikita, J. Stephen ;Roberts, Jamie ;Agoritsas, Thomas ;Bertschy, Sonja ;Boroli, Filippo ;Camsooksai, Julie ;Du, Bin ;Heen, Anja Fog ;Lu, Jianyou ;Mella, Jose M. ;Vandvik, Per Olav ;Wise, Robert ;Zheng, Yue ;Liu, Lihong ;Siemieniuk, Reed A. C. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ-BRITISH MEDICAL JOURNAL. 10.1136/bmj.l6722. (SCIE, Q1,IF-2020=39.89)
11. Wang, Ying ;Ye, Zhikang ;Ge, Long ;Siemieniuk, Reed A. C. ;Wang, Xin ;Wang, Yingkai ;Hou, Liangying ;Ma, Zhuo ;Agoritsas, Thomas ;Vandvik, Per Olav ;Perner, Anders ;Moller, Mo rten H. ;Guyatt, Gordon H. ;Liu, Lihong. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. BMJ-BRITISH MEDICAL JOURNAL. 10.1136/bmj.l6744. (SCIE, Q1,IF-2020=39.89)